Historic Acquisition of The Iconic Grosvenor House Hotel by Ashkenazy Acquisition Corp
7.7.2017 20:15 | Business Wire
One of the world’s most iconic assets, The Grosvenor House Hotel in London, was acquired by U.S. real estate firm Ashkenazy Acquisition Corp on 6th July 2017 in what constitutes the most significant single asset hotel deal in U.K. history. Financial terms were not disclosed.
Ashkenazy Acquisition Corp has one of the largest portfolios of iconic assets in the U.S. and this acquisition reflects a continued aggressive focus from Ashkenazy Acquisition Corp to deploy, over the next 24 months, an additional 2 billion euro of equity in acquiring global iconic assets.
Other iconic assets owned by Ashkenazy include Union Station (Washington, D.C.), Faneuil Hall Marketplace (Boston), 625 Madison Avenue (New York), Bayside Marketplace (Miami) and Barneys New York (New York & Los Angeles). Recently, Ashkenazy acquired a stake in the famed Plaza Hotel in New York City.
About The Grosvenor House Hotel: The Grosvenor House Hotel, featuring a tradition of luxury, was built in the 1920s and opened in 1929 on the site of Grosvenor House located on Park Lane, Mayfair. Fully refurbished with a world-class architectural design, The Grosvenor House Hotel brings 350 years of London history and tradition to life in one of the most prestigious luxury markets globally.
About Ashkenazy Acquisition Corp: Ashkenazy Acquisition Corp is a private real estate investment firm with a portfolio valued in excess of $10 billion focusing on retail, hospitality, office and residential. http://www.aacrealty.com/
Ashkenazy Acquisition Corp
Melanie Sessa, 212-213-4444
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Major Terrorist Plot Foiled in Saudi Arabia, Ministry of Interior Announces21.7.2017 18:33 | Pressemelding
The following is a statement from Saudi Arabia’s Ministry of Culture and Information: This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005575/en/ Weapons and other items found in the possession of the three terrorists are an indication of the ugliness and severity of the acts of terrorism they were planning to carry out, victimizing innocent lives and private and public property. (Photo: ME NewsWire) The Saudi Ministry of Interior has announced that a major terrorist attack was prevented by security services in the city of Saihat in the Qatif governorate. On the evening of Friday, July 14th, security services intercepted a stolen Toyota Corolla vehicle in a busy, built-up district of the city. As the stolen vehicle was surrounded by security services, three men in the ca
Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV21.7.2017 12:09 | Pressemelding
Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single tablet regimen (STR). If approved, it will be the only darunavir-based STR indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg, with genotypic testing guiding use. This STR combines the proven efficacy and durability of darunavir with the improved renal laboratory and bone mineral density profile of F/TAF as compared to F/TDF (tenofovir disoproxil fumarate), and will be the only treatment that could deliver the adherence advantag
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy21.7.2017 11:26 | Pressemelding
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the approval of Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for use in the 28 countries of the European Union, as well as Norway, Liechtenstein and Iceland. David Meek, Chief Executive Officer of Ipsen, said: “The positive CHMP opinion for Xermelo ® is an important milestone towards providing innovative s
Schlumberger Announces Second-Quarter 2017 Results21.7.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the second quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2017 Mar. 31, 2017 Jun. 30, 2016
NRI Secure Launches Japan's First "Blockchain Assessment" Service21.7.2017 07:00 | Pressemelding
NRI SecureTechnologies, Ltd. (President: Jun Odashima; hereinafter NRI Secure), a leading provider of information security solutions in Japan, has begun providing Japan’s first-ever*1 “Blockchain Assessment,” a security Assessment service designed for systems and services which use blockchain technology*2. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005012/en/ Overview of the "Blockchain Assessment" Service (Graphic: Business Wire) As the blockchain technology has become more widespread, the presence of security-related vulnerabilities has also become increasingly apparent. In particular, with regard to smart contracts, *3 one of a constituent element of services using the blockchain, a cyberattack carried out on any vulnerable programs could lead to major threats or eve
Business Figures for the First Half of 2017: Sartorius Continues to Grow21.7.2017 05:00 | Pressemelding
Sartorius (FWB:SRT), a leading international laboratory and pharmaceutical equipment supplier, continues on the growth track. In the first half of 2017, solid organic business development and two acquisitions led to a significant increase in sales revenue and earnings1. "Sartorius has continued its dynamic, profitable development," said CEO and Executive Board Chairman Dr. Joachim Kreuzburg in commenting on the company's first-half performance. "Both divisions achieved solid organic growth in an environment that was especially challenging in North America, and have made quick progress in integrating the businesses most recently acquired. In the Lab Products & Services Division, the bioanalytics unit newly created by our acquisitions has already contributed significant revenues and earnings. We see further considerable growth potential ahead for this business just as for the
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom